PharmaIN Corporation Revenue and Competitors

PharmaIN is a proprietary peptide drug development company. We leverage our proprietary knowledge and expertise in peptide delivery technologies and unique drug targets to create major medical breakthroughs and accelerate the development of new drug candidates. Our programs include: refractory ascites, lung diseases, cancer immunotherapy and refractory hypertension. We are funded by NIH awards of over $7M for the development of several peptides and proteins (biologics), and by angel investments. PharmaIN's business model has two primary directives. The first is to continue to pursue NIH funding toward in-house development of products, the second is to solicit partnerships with a variety of pharmaceutical and biotechnology companies to co-develop therapeutic drug formulations. PGC does not bind the drug covalently, using a high affinity interaction to increase half-life and preferentially accumulate in areas of enhanced vascular permeability, such as infection, solid tumors, and inflammation. PGC was initially developed at Harvard University and Massachusetts General Hospital (MGH) and has been expanded by PharmaIN to include over 15 families of issued and pending patents. We are funded by NIH awards of over $6M for the development of several peptides and proteins (biologics), and by angel investments. PharmaIN's business model has two primary directives. The first is to continue to pursue NIH funding toward in-house development of products, the second is to solicit partnerships with a variety of pharmaceutical and biotechnology companies to co-develop therapeutic drug formulations. PGC can be very useful for “bio-betters” since performance can be improved without alteration of the drug.